Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580125 · ClinicalTrials.gov registry record · Phase 2
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 20
- Study locations
NCT00580125 is a Phase 2 study of Schizophrenia that has completed, run by Pfizer. The registered enrollment target is 164 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00580125, a Phase 2 study of Schizophrenia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Aripiprazole
- DRUG PF-00217830
Study Locations (20)
Other
- Pfizer Investigational Site - Pune
- Pfizer Investigational Site - Khot'kovo
- Pfizer Investigational Site - Moscow
- Pfizer Investigational Site - Saint Petersburg
- Pfizer Investigational Site - Saint Petersburg
Missouri
- Pfizer Investigational Site - Bridgeton
- Pfizer Investigational Site - Florissant
- Pfizer Investigational Site - Saint Charles
Karnataka
- Pfizer Investigational Site - Bangalore
- Pfizer Investigational Site - Mangalore
- Pfizer Investigational Site - Udupi
California
- Pfizer Investigational Site - Garden Grove
- Pfizer Investigational Site - Torrance
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Michigan
- Pfizer Investigational Site - Detroit
New York
- Pfizer Investigational Site - Brooklyn
Maharashtra
- Pfizer Investigational Site - Pune
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580125
The ClinicalTrials.gov registry entry for NCT00580125 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00580125 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Missouri, Karnataka.
Frequently Asked Questions
What is clinical trial NCT00580125 about?
NCT00580125 is a clinical study titled "Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia". The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
What is the current status of trial NCT00580125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2007-11. Estimated completion is 2008-09.
What conditions does trial NCT00580125 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00580125?
The interventions under investigation include: Placebo (OTHER), Aripiprazole (DRUG), PF-00217830 (DRUG).
Who is sponsoring clinical trial NCT00580125?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00580125 being conducted?
This trial has 20 study locations across California, District of Columbia, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.